Andere Sprachen Perseus Proteomics Inc.

Aktien

A3CSUD

JP3836800007

4882

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 11.06.2024			% 5 Tage	% 1. Jan.
324 ^JPY	+1,89 %		+2,21 %	-47,57 %

10.05.	Perseus Proteomics Inc. kündigt Verzögerung des Endes der klinischen Phase I-Studie für Polycythemia Vera an	CI
14.02.	Perseus Proteomics Inc. meldet Ergebnis für die neun Monate bis zum 31. Dezember 2023	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	10.05.
Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)	07.03.
Perseus Proteomics Inc. announced that it expects to receive ¥1.566 million in funding	20.02.
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	14.02.
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	02.02.
Perseus Proteomics Secures Japanese Patent for Blood Cancer Drug Candidate	27.12.
Perseus Proteomics Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	13.11.
Perseus Proteomics Successfully Enrolls Patients in Phase I Clinical Trial of Anti-TfR1 Antibody for Polycythemia Vera	23.10.23
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)	20.10.23
Perseus Proteomics Launches Sales of Three Antibodies	12.10.23
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents	11.10.23
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology	27.09.23
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia	22.09.23
Perseus Proteomics, Inc. Announces MOU Agreement on Joint Research on Super-Neutralizing Antibody with University of Toyama and Toyama Prefecture	29.08.23
Perseus Proteomics Inc. Reports Impairment Loss for the First Quarter of the Fiscal Year 2023	14.08.23
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	14.08.23
Perseus Proteomics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14.08.23
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003	29.05.23
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	12.05.23
Perseus Proteomics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12.05.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Perseus Proteomics Inc.

Aktien

A3CSUD

JP3836800007

4882

Andere Sprachen

Filter